Compare Quest Diagnostics Inc (DGX) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tesla, Inc. — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Tesla, Inc. trades at $327 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 50× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| DGX | TSLA | |
|---|---|---|
Market Cap | $26.21B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $489.88 |
52-Week Low | $173.49 | $298.16 |
Enterprise Value | $31.97B | $1.29T |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Tesla (TSLA) trades at $326.95, down 1.18% on the day, amid a bearish technical signal and mixed fundamentals. The stock faces pressure from a recent earnings miss in Q2 2026 but maintains strong operating cash flow of $14.75B in 2025. Recent news highlights regulatory approval for its driver-assistance software in Europe (Reuters, 2026-04-10) and a surge in German registrations, though competition and valuation concerns persist.
Outlook remains bifurcated: long-term growth hinges on AI and autonomy execution, but near-term risks include high P/E of 308.16 and softening auto demand. Analyst consensus price target of $393.87 suggests upside potential if innovation milestones are met, yet investor patience is required amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
